triphenylphosphine has been researched along with docetaxel anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battogtokh, G; Chimed, G; Cho, J; Gotov, O; Jeong, TH; Kang, JH; Ko, YT | 1 |
| Chen, D; Hu, H; Li, J; Pan, S; Qiao, M; Shi, M; Yang, C; Zhang, J; Zhao, X | 1 |
2 other study(ies) available for triphenylphosphine and docetaxel anhydrous
| Article | Year |
|---|---|
Triphenylphosphine-docetaxel conjugate-incorporated albumin nanoparticles for cancer treatment.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Humans; Mice; Mitochondria; Nanoparticles; Neoplasms; Organophosphorus Compounds; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2018 |
Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine-docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Survival; Docetaxel; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Concentration; Liposomes; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Mitochondria; Organophosphorus Compounds; Receptors, Eph Family; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |